logo
    Although survival rates are very useful for monitoring the effects of early cancer detection and treatment, at present there are only limited population-based estimates of long-term survival rates in Korea. Furthermore, published data are only available for 5-year survival; 10-year survival rates have hitherto not been reported. We therefore analysed data from the Korean National Cancer Incidence Database between 1993 and 2007 and followed through into 2008 to estimate long-term survival rates and trends at 5 and 10 years after diagnosis of all cancers combined. Further analysis was conducted on the 19 most common cancers in Korea. From 1993 to 2007, the 10-year relative survival rates (RSRs) for all cancer types combined were 36.3% and 56.4% in Korean men and women, respectively. The 10-year RSRs for all cancers combined improved from 29.5% and 50.5% during 1993-1998 to 39.2% and 58.9% during 1999-2007 in Korean men and women, respectively. From 1993 to 2007, the 5-year and 10-year RSRs thus improved in both sexes for the most common cancers. In the 75 years and older group, increases of the 5-year and 10-year RSR for all combined, and for most of the major cancers were lower than all other age groups. This study provides population-based estimates of long-term survival and confirms improvements of long-term survivals for all cancer sites and for most of the major cancer sites. Improvements of survival for young patients are more significant than for older patients. The results may help clinicians and patients assess long-term prognosis.
    Relative survival
    Citations (7)
    population-based survival analyses are fundamental to assess the impact of public health interventions and new therapies in cancer control. This monograph updates previous reports on cancer patient survival in Italy up to the year 2007.we extracted from the Network of Italian Cancer Registries (AIRTUM) database over 1,490,000 records of tumours diagnosed during 1990-2007 and followed up to the end of 2008, including all multiple tumours. We used the Ederer II method to estimate relative survival (RS) for 29 different types of neoplasm. Five-year relative survival rates were analysed by gender and macroarea. Trends in 5-, 10- and 15-year RS were studied by gender over six 3-year diagnostic periods, from 1990 to 2007. Conditional 5-year RS was also computed by gender and macroarea. Hybrid approaches were applied to exploit the recent survival experiences of cases diagnosed up to 2007. Adjustment for age was performed using EUROCARE weights. Additional sections describe cancer patient survival in childhood and in elderly patients and provide a comparison of cancer patient survival rates in Italy with those of other countries.Standardized 5-year RS for all tumours but skin in 52% for men and 61% for women. Patient survival has improved for almost all types of cancer: from 1990 to 2007 5-year RS has increased by 15% for all cancers but skin; the exceptions are some cancers with poor prognosis, where patient survival has remained basically unchanged. In males, RS was usually lower than in females, but trend analysis shows that the gap is narrowing. We also report persisting lower RS in southern Italy: 5-year RS in the South is usually from 4% to 10% lower than in the North and Centre.this study provides valuable information for all stakeholders in cancer control, both in Italy and elsewhere. Increasing survival reflects improvements in various areas of cancer control. On the other hand, delayed diagnosis and suboptimal management are consistent with the reported differences in survival within the country.
    Relative survival
    Cancer Survival
    Citations (21)
    Little is known about survival and quality of life (QoL) of patients treated by transcatheter aortic valve implantation (TAVI) compared to the age- and sex-matched general population. In this study we compared subgroups of the National Heart Registration TAVI cohort to the Dutch age- and sex-matched population at the level of survival and QoL.
    Relative survival
    Citations (16)
    To gain insight into the survival of cancer patients in order to evaluate any improvement in cancer care.A retrospective population-based cohort study.Data from the Netherlands Cancer Registry were used for this study. For all patients diagnosed with cancer in the Netherlands between 1989 and 2008, information on vital status was obtained from hospitals, municipalities and the Municipal Personal Records Database. Age-standardised, relative survival rates per cancer type were calculated.The 5-year relative survival for all types of cancer combined increased from 47% in 1989-1993 to 59% in 2004-2008. This increase was greater in males than in females (from 40% to 55% and from 55% to 62%, respectively). The most striking improvements in survival were observed in breast, prostate and colorectal cancers, probably for reasons differing for each cancer type. Patients with chronic myeloid leukaemia showed the greatest gain in survival (43%). Survival rates in older patients were generally worse in comparison to those in younger patients, especially in case of head and neck cancer, ovarian cancer and haematological malignancies. The survival gap between older and younger patients has increased over the last 20 years. The 10-year survival rate for most cancer types was not much lower than the 5-year rate, except in chronic and indolent haematological malignancies and cancers that may reoccur after a long time, such as breast and prostate cancer.The increase in survival rates of cancer patients in the Netherlands, attributed to early detection and improved treatment, could represent either an increase in the number of patients cured or to cancer patients living longer lives. A potential area for further improvement is especially notable in the elderly. This is even more important given the ageing population.
    Relative survival
    Citations (10)
    To report 5-year relative cancer survival probabilities conditional on having already survived > or = 1 years after the initial diagnosis for 11 cancer sites, diagnosed during 1990-2001 and followed through 2006.Analyses are based on 1,151,496 cancer cases in population-based cancer registries in the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.The 5-year relative conditional survival probability tended to improve with each year already survived. Improvement was greatest for more lethal cancers (e.g., lung or pancreas) and for cases with a more advanced stage at diagnosis. The 5-year relative survival probability conditional on already having survived 5 years exceeded 90% for locally staged prostate cancer, melanoma (whites only), breast cancer (females only), corpus uteri cancer, urinary bladder cancer, Hodgkin's lymphoma, rectal cancer, colon cancer, ovary cancer, and pancreatic cancer. Only lung cancer did not reach 90%. For these cancer sites combined, 5-year relative survival probability conditional on already having survived 5 years averaged about 85% for regionally staged disease, 68% for distant staged disease, and 87% for unknown staged disease. The 5-year relative conditional survival probability tended to be significantly lower among patients diagnosed at older ages, among males, among nonwhites, and among those diagnosed during 1990-1995 compared with later years.Conditional survival probability estimation provides further useful prognostic information to cancer patients, tailored to the time already survived since diagnosis.
    Relative survival
    Epidemiology of cancer
    Although we usually report 5‐year cancer survival using population‐based cancer registry data, nowadays many cancer patients survive longer and need to be followed‐up for more than 5 years. Long‐term cancer survival figures are scarce in Japan. Here we report 10‐year cancer survival and conditional survival using an established statistical approach. We received data on 1 387 489 cancer cases from six prefectural population‐based cancer registries in Japan, diagnosed between 1993 and 2009 and followed‐up for at least 5 years. We estimated the 10‐year relative survival of patients who were followed‐up between 2002 and 2006 using period analysis. Using this 10‐year survival, we also calculated the conditional 5‐year survival for cancer survivors who lived for some years after diagnosis. We reported 10‐year survival and conditional survival of 23 types of cancer for 15–99‐year‐old patients and four types of cancer for children (0–14 years old) and adolescent and young adults (15–29 years old) patients by sex. Variation in 10‐year cancer survival by site was wide, from 5% for pancreatic cancer to 95% for female thyroid cancer. Approximately 70–80% of children and adolescent and young adult cancer patients survived for more than 10 years. Conditional 5‐year survival for most cancer sites increased according to years, whereas those for liver cancer and multiple myeloma did not increase. We reported 10‐year cancer survival and conditional survival using population‐based cancer registries in Japan. It is important for patients and clinicians to report these relevant figures using population‐based data.
    Relative survival
    Citations (146)
    Abstract Cixian is one of the high‐risk areas for upper gastrointestinal cancer in China and the world. From 2005, comprehensive population‐based screening for upper gastrointestinal cancers has been conducted in Cixian. The aim of this study was to investigate population‐based cancer survival from 2003 to 2013 and to explore the effect of screening on upper gastrointestinal cancer survival in Cixian. Observed survival was estimated using the life table method. The expected survival from the general population was calculated using all‐cause mortality data from the population of Cixian with the EdererII method. Cixian cancer registry, with a total coverage of 6.88 million person years, recorded 19,628 cancer patients diagnosed during 2003–2013. In Cixian, from 2003 to 2013, there were 19,628 newly cancer cases and 13,984 cancer deaths, with an incidence rate of 285.37/100,000 and mortality rate of 203.31/100,000. The overall five‐year relative cancer survival for patients diagnosed in Cixian in 2003–2013 was 22.53%. The relative survival for all cancers combined in Cixian had an overall upward trend from 2003 to 2013. Among upper gastrointestinal cancer in Cixian, the five‐year relative survival for cardia gastric cancer was highest at 30.42%, followed by oesophageal cancer at 25.37% and noncardia gastric cancer at 18.93%. In 2013, the five‐year relative survival for oesophageal cancer, cardia gastric cancer, and noncardia gastric cancer patients aged 45–69 years was 39.97% (95% CI: 34.52–45.43%), 51.74% (95% CI: 42.09–60.86%), and 37.43% (95% CI: 26.93–48.17%), respectively, the absolute values increasing 14.11%, 16.71%, and 14.92% compared with that in 2003. There is an increasing trend in overall survival for upper gastrointestinal cancer with early screening and treatment of cancer in Cixian.
    Relative survival
    Citations (21)
    Purpose In Korea, anal cancer is rare disease entity with specific clinical characteristics. Therefore, no survival analysis with a sufficient patient population has been performed. The aim of this study was to evaluate the characteristics of Korean anal cancer, focusing on the survival according to tumor histologies, sex, and a specific age group, using the nationwide cancer registry. Methods Using the Korea Central Cancer Registry, we analyzed a total of 2,552 cases from 1993 to 2010. We assessed the 5-year relative survival by using tumor histology. In addition, survival differences of Surveillance Epidemiology and End Results (SEER) stage were analyzed for both sexes and for young-age cancer (younger than 40 years) and advanced-age cancer (older than 70 years). Results The 5-year relative survival among anal cancer patients increased from 38.9% for the period 1993-1995 to 65.6% for the period 2006-2010. The anal squamous cell carcinoma was the most common histology and showed better survival than other types of cancer. Females demonstrated better survival than males in all SEER stages. The 5-year survivals for patients in whom anal cancer developed before the age of 40 and at or after the age of 40 were 62.4% and 51.6%, respectively. The 5-year survival for patients in whom cancer developed at or after the age of 70 was much worse than that for patients in whom the cancer had developed prior to that age. Conclusion Korean anal cancer has certain distinctive characteristics of survival according to tumor histology, sex, and age. Despite limitations on available data, this study used the nationwide database to provide important information on the survival of Korean patients with anal cancer. Keywords: Anal neoplasms; Korean; Survival
    Relative survival
    Citations (12)